Scarica l'app Stockscreener
18.10
1.74%
-0.32
Dopo l'orario di chiusura:
17.78
-0.32
-1.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.42
Aprire:
$18.22
Volume 24 ore:
1.56M
Relative Volume:
0.47
Capitalizzazione di mercato:
$1.91B
Reddito:
$2.18B
Utile/perdita netta:
$-64.32M
Rapporto P/E:
-18.77
EPS:
-0.9641
Flusso di cassa netto:
$91.18M
1 W Prestazione:
+7.87%
1M Prestazione:
+0.78%
6M Prestazione:
+1.74%
1 anno Prestazione:
-10.84%
Intervallo 1D:
$17.69
$18.26
Intervallo di 1 settimana:
$16.38
$18.73
Portata 52W:
$14.68
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
18.10 | 1.94B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2025-12-09 | Iniziato | Wedbush | Outperform |
| 2025-11-05 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-09-22 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Iniziato | Bernstein | Mkt Perform |
| 2025-07-29 | Reiterato | H.C. Wainwright | Sell |
| 2025-07-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Iniziato | Citigroup | Sell |
| 2025-07-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-07-21 | Downgrade | Needham | Hold → Underperform |
| 2025-07-21 | Downgrade | UBS | Buy → Neutral |
| 2025-07-18 | Downgrade | Needham | Buy → Hold |
| 2025-06-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2025-06-17 | Iniziato | Wolfe Research | Peer Perform |
| 2025-06-16 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Downgrade | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SRPT6155802 Latest News and Headlines - TradingView
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - marketbeat.com
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
SRPT|Sarepta Therapeutics Inc|Price:17.890|Chg%:-0.530 - TradingKey
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta (SRPT) Q2 2026 Earnings Call Transcript - AOL.com
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT - marketbeat.com
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - The National Law Review
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside - DirectorsTalk Interviews
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - Sahm
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A - TradingView
Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A - TradingView
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - Sahm
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen - marketbeat.com
(SRPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
State Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - Stock Titan
Traders Purchase Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingView
Oppenheimer Adjusts PT on Sarepta Therapeutics to $35 From $37, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market - Streetwise Reports
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Q2 Earnings Call Highlights - marketbeat.com
Is Sarepta Therapeutics Inc (SRPT) a Value Opportunity After Q2 Loss? GF Score: 63/100, Revenue at $401.3M - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highligh - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ... - Yahoo Finance
Sarepta Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SRPT) 2026-08-06 - Seeking Alpha
BlackRock, Inc. Adds to Sarepta Therapeutics Inc (SRPT) -- Shares Look 88% Undervalued on GF Value - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS - marketbeat.com
Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Sarepta beats Q2 2026 estimates as shares rise after hours - Investing.com
Sarepta rises on quarterly double-line beat - Seeking Alpha
Sarepta Therapeutics: Q2 Earnings Snapshot - Barchart.com
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q2 Adjusted EPS $0.64 per Share - marketscreener.com
Sarepta Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q2 Revenue $401.3M, vs. FactSet Est of $366.4M - marketscreener.com
Sarepta Therapeutics Inc. R (AB3A.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Sarepta Therapeutics 2Q 2026: Revenue $328.7M, EPS $(0.05) — 10-Q Summary - TradingView
Sarepta Therapeutics, Inc. Revises Revenue Guidance for the Year 2026 - marketscreener.com
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):